Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02740699 · ClinicalTrials.gov registry record · Phase 4
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
A Phase 4 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT02740699 is a Phase 4 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 79 participants.
The verdict
NCT02740699, a Phase 4 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
Background: Coronary artery disease causes plaque in arteries. This can cause stroke or heart disease. Drugs called statins might shrink plaque. Researchers want to study how CT scanning can determine if an individuals arterial plaque has decreased while taking statins. Objectives: To measure the change in coronary artery plaque volume in people treated with high-intensity statin therapy using CT and MRI scans. To study the metabolic activity of plaque in arteries. To determine how well plaque measurements from heart CT scans can be replicated. Eligibility: Men ages 40-75 and women ages 40-75 who are good candidates for statin treatment Design: Visit 1: participants will be screened with: * Medical history * Blood tests * Heart MRI and CT scan: An IV inserted into an arm or hand vein removes blood and injects contrast, and medicine if needed. Participants lie on a table that slides into a machine that takes pictures of the body. For the CT scan, if their heart rate is too high, they get medicine to lower it. They breathe in a special way, holding their breath for 5 seconds. Participants will begin high-intensity statin treatment. Participants will have 7 more visits over 3 years. All visits include blood tests and medication review. Some may also include: * Statin treatment adjustment * CT scan * MRI scan * Physical exam Participants may join the PET Substudy. This includes 5 more visits during the study. These include: * Getting an IV in an arm vein * Blood tests * PET scans: They fast 12 hours before. Participants may join the Reproducibility Substudy if they had a slow heart rate during their first CT scan. This includes 1 additional heart CT scan 4 weeks later.
Interventions
- DRUG Rosuvastatin
- DRUG Atorvastatin
- RADIATION Cardiac Computed Tomography (CT)
- RADIATION Cardiac Magnetic Resonance Image (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2016-04-11 |
| Est. Completion | 2022-03-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02740699
The ClinicalTrials.gov registry entry for NCT02740699 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rosuvastatin is the first listed.
NCT02740699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02740699 about?
NCT02740699 is a clinical study titled "CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction". Background: Coronary artery disease causes plaque in arteries. This can cause stroke or heart disease. Drugs called statins might shrink plaque. Researchers want to study how CT scanning can determine if an individuals arterial plaque has decreased while taking statins. Objectives: To measure the...
What is the current status of trial NCT02740699?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2016-04-11. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT02740699?
The interventions under investigation include: Rosuvastatin (DRUG), Atorvastatin (DRUG), Cardiac Computed Tomography (CT) (RADIATION), Cardiac Magnetic Resonance Image (MRI) (RADIATION).
Who is sponsoring clinical trial NCT02740699?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.